1-3 of 3
Mary Ann T. Go
Close
Sort by
Journal Articles

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

Andrew G. Polson, Bing Zheng, Kristi Elkins, Jeffery Lau, Mary Ann T. Go, Suzie J. Scales, Shang-Fan Yu, Marta Chesi, P. Leif Bergsagel, MD, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 3836.
https://doi.org/10.1182/blood.V114.22.3836.3836
Published: 2009
Journal Articles

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

David Dornan, Fiona Bennett, Yvonne Chen, Mark Dennis, Dan Eaton, Kristi Elkins, Dorothy French, Mary Ann T. Go, Andrew Jack, Jagath R. Junutula, Hartmut Koeppen, Jeffrey Lau, Jacqueline McBride, Andy Rawstron, Xiaoyan Shi, Nancy Yu, Shang-Fan Yu, Peng Yue, Bing Zheng, Allen Ebens, Andrew G. Polson
Journal: Blood
Blood (2009) 114 (13): 2721–2729.
https://doi.org/10.1182/blood-2009-02-205500
Published: 2009
Includes: Supplemental data
Journal Articles

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

Andrew G. Polson, Fiona L Bennett, Yvonne Chen, Mark Dennis, Dan Eaton, Allen Ebens, Kristi Elkins, Dorothy French, Mary Ann T. Go, Andrew S Jack, Jagath Junutula, Hartmut Koeppen, Jeffery Lau, Jacqueline McBride, Lily Shi, Andy Rawston, Shang-Fan Yu, Peng Yue, Bing Zheng, David Dornan
Journal: Blood
Blood (2008) 112 (11): 2618.
https://doi.org/10.1182/blood.V112.11.2618.2618
Published: 2008